small molecule

DESONATE

DESONIDE

Loss of exclusivity—loss of exclusivity

CompanyLEO PHARMA AS

Drug detail

Brand name	DESONATE
Active ingredient	DESONIDE
Strength	0.05% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	GEL
Route	TOPICAL
Modality	Small molecule
FDA approval	October 2006
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.